December 2011 Heart Health

Janssen Pharmaceuticals' Xarelto

December 07, 2011

Rx Product News Profile

The FDA approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism following hip or knee replacements and for the prevention of stroke in patients with nonvalvular atrial fibrillation.